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Association Between Modiﬁable Risk Factors and Pharmaceutical
Expenditures Among Adults With Atherosclerotic Cardiovascular
Disease in the United States: 2012–2013 Medical Expenditures
Panel Survey
Joseph A. Salami, MD, MPH; Javier Valero-Elizondo, MD, MPH; Oluseye Ogunmoroti, MD, MPH; Erica S. Spatz, MD, MHS;
Jamal S. Rana, MD, PhD; Salim S. Virani, MD, PhD; Ron Blankstein, MD; Adnan Younus, MD; Alejandro Arrieta, PhD;
Michael J. Blaha, MD, MPH; Emir Veledar, PhD; Khurram Nasir, MD, MPH
Background-—Atherosclerotic cardiovascular disease (ASCVD) causes most deaths in the United States and accounts for the
highest healthcare spending. The association between the modiﬁable risk factors (MRFs) of ASCVD and pharmaceutical
expenditures are largely unknown.
Methods and Results-—We examined the association between MRFs and pharmaceutical expenditures among adults with ASCVD
using the 2012 and 2013 Medical Expenditure Panel Survey. A 2-part model was used while accounting for the survey’s complex
design to obtain nationally representative results. All costs were adjusted to 2013 US dollars using the gross domestic product
deﬂator. The annual total pharmaceutical expenditure among those with ASCVD was $71.6 billion, 33% of which was for
medications for cardiovascular disease and 14% medications for diabetes mellitus. The adjusted relationship between MRFs and
pharmaceutical expenditures showed signiﬁcant marginal increase in average annual pharmaceutical expenditure associated with
inadequate physical activity ($519 [95% conﬁdence interval (CI), $12–918; P=0.011]), dyslipidemia ($631 [95% CI, $168–1094;
P=0.008]), hypertension: ($1078 [95% CI, $697–1460; P<0.001)], and diabetes mellitus ($2006 [95% CI, $1470–2542]). Compared
with those with optimal MRFs (0–1), those with average MRFs (2–3) spent an average of $1184 (95% CI, $805–1564; P<0.001)
more on medications, and those with poor MRFs (≥4) spent $2823 (95% CI, $2338–3307; P<0.001) more.
Conclusions-—Worsening MRFs were proportionally associated with higher annual pharmaceutical expenditures among patients
with established ASCVD regardless of non-ASCVD comorbidity. In-depth studies of the roles played by other factors in this
association can help reduce medication-related expenditures among ASCVD patients. ( J Am Heart Assoc. 2017;6:e004996.
DOI: 10.1161/JAHA.116.004996.)
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C ardiovascular disease (CVD) remains the leading causeof morbidity and mortality globally,1 and atherosclerotic
cardiovascular disease (ASCVD) is the most common type,
accounting for >370 000 deaths annually.2 In addition to the
impact on mortality, ASCVD causes signiﬁcant loss of quality
of life and is responsible for the highest healthcare
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expenditure for any single class of disease.1 In 2011, the
estimated annual direct cost for CVD and stroke in the United
States was about $196 billion.1 Incidence, associated mor-
bidity, disability, mortality, and healthcare costs have been
shown to depend largely on modiﬁable risk factors (MRFs) for
CVD.3–6
Expenditures on prescription medication in the US general
population formed 9.8% of total healthcare spending in 2014,7
and in 2012, 26.1% of total healthcare expenditures among
adults with CVD were for medications.8 Although few studies
have reported incremental healthcare costs associated with
worsening cardiovascular risk factor proﬁles among patients
with diagnosed CVD,9,10 the association between MRFs and
pharmaceutical expenditures in the United States has not
been examined.
Considering the economic impact of ASCVD and the
signiﬁcant contribution of pharmaceutical expenditure to
overall healthcare expenditure, we aimed to examine the
association between MRFs and pharmaceutical expenditures
(both overall and medication-speciﬁc) in a nationally repre-
sentative population with established ASCVD.
Methods
Study Design and Population
We conducted a retrospective study of US adults aged
≥40 years with established ASCVD using data from the 2012
and 2013 Medical Expenditure Panel Survey (MEPS) database.
MEPS, sponsored by the Agency for Healthcare Research and
Quality (AHRQ), is a national survey of individuals, families,
their medical providers (for medical conditions), and employ-
ers, to obtain patients’ healthcare resource utilization and
expenditure. Each year, the MEPS Household Components
(MEPS-HC) sample is drawn from respondents of the previous
year’s National Health Interview Survey. It has an overlapping
panel design, with each panel composed of randomly sampled
noninstitutionalized US civilians. Participants are interviewed
every 6 months over a period of 30 months, and their
responses are reported annually to provide nationally repre-
sentative estimates of sociodemographic characteristics,
medical conditions, and healthcare utilization and costs.11,12
Interviews were conducted over the telephone with partici-
pants, and their physicians, hospitals, and pharmacies were
contacted to obtain additional healthcare use and cost data.
The AHRQ researchers assigned person weights and variance
estimation strata to participants after data collection to
reﬂect survey nonresponse and population totals of the
participants surveyed.13
We merged the MEPS-HC full-year consolidated, medical
conditions, and prescribed medicines ﬁles for 2012 and 2013
for this study.14,15 Pooling this 2-year data afforded us a
larger and analyzable population of adults with ASCVD. Race
and ethnicity were determined using the MEPS-deﬁned
categories that allow respondents to report multiple Hispanic
ethnicities.
Because MEPS consists of publicly available, de-identiﬁed
data ﬁles, this study was exempt from institutional review
board, in accordance with US Department of Health and
Human Services guidelines. Written consent was obtained
from participants to contact them for interviews and to
contact their healthcare providers (clinicians and pharmacies).
We classiﬁed participants as having ASCVD using the
International Statistical Classiﬁcation of Diseases, Ninth Revi-
sion, Clinical Modiﬁcation (ICD-9 CM) diagnosis of the
condition (Table S1)16,17 and/or self-reported history of
diagnosis of coronary heart disease, angina, myocardial
infarction, and/or stroke. Our study population was limited
to noninstitutionalized US adults with established ASCVD who
were ≥40 years at the time of the survey (ASCVD is
uncommon among younger adults), had a body mass index
(calculated as weight in kilograms divided by height in meters
squared) of ≥18.5 kg/m2 (underweight individuals generally
represent a sicker population),18 and who had a ﬁnal person-
weight >0 to be representative of the national population at
the time of the survey (Figure S1).
Pharmaceutical Expenditures
During the household interview, respondents supplied the
name of any prescribed medicine that they or their family
members purchased or otherwise obtained during the refer-
ence period. They were also asked for permission to obtain
payment data and other information from pharmacies. With
the written permission from participants, pharmacies were
contacted to obtain information on the medication name,
national drug code, strength, quantity, date ﬁlled, and amount
paid. The multisourced, person-level medication information
was then included in MEPS prescribed medicine ﬁles and
linked to the Multum Lexicon databases by AHRQ researchers
to assign the drugs into classes.19 The codes we used to
group CVD, diabetes, and other classes of medications are
shown in Table S2. More details on the collection and
management of pharmaceutical data in MEPS are provided
elsewhere.20 For each drug prescribed, the exact dollar
amount paid was reported. Using these cost data, we
calculated expenditures speciﬁc to the different classes of
drugs. All expenditures were adjusted to constant 2013 US
dollars using the gross domestic product deﬂator.
Modiﬁable Risk Factors and Comorbidity Burden
The MRFs examined in this study included inadequate
physical activity, obesity, smoking, dyslipidemia,
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hypertension, and diabetes mellitus. We used responses from
the self-administered questionnaire to determine the MRF
status of participants, and we classiﬁed each as a binary
variable (favorable [0] versus unfavorable [1]). Any participant
who did not engage in moderate vigorous physical activity 5
times a week; had a BMI ≥30 kg/m2; was a smoker at the time
of interview; or reported a diagnosis of a cholesterol disorder,
hypertension, or diabetes mellitus was classiﬁed as having
unfavorable MRFs. Based on the presence of these individual
risk factors, survey participants were categorized as poor (≥4
cardiovascular risk factors), average (2–3 cardiovascular risk
factors), or optimal (0–1 cardiovascular risk factor). We also
determined the contribution of comorbidity to the association
between MRFs and pharmaceutical expenditures and com-
pared the marginal pharmaceutical expenditures associated
with comorbidity and those associated with MRF proﬁle.
Participants’ comorbidity burden was assessed using the
grouped Charlson Comorbidity Index (GCCI), which has been
described elsewhere.21,22 For our analyses, however, we
modiﬁed the GCCI by excluding acute myocardial infarction,
congestive heart failure and peripheral vascular disease from
our estimation of GCCI score, since these were included in our
deﬁnition of ASCVD; and diabetes mellitus, since it was
considered a cardiovascular risk factor. We had 3 categories
for GCCI: no comorbidity (0), 1 long-term condition (1), and ≥2
long-term conditions present other than CVD and/or diabetes
mellitus (2; Table S2).
Covariates
We considered age, sex, race/ethnicity, and family income as
factors that were also associated with pharmaceutical
expenditures; therefore, we used these as covariates in the
determination of the association between MRFs and pharma-
ceutical expenditures. Participant age as of the last day of the
survey was classiﬁed into 3 categories: 40 to 64, 65 to 74,
and ≥75 years. We had 5 categories of race and ethnicity:
non-Hispanic white, non-Hispanic black, Hispanic, Asian, and
other (American Indian, Alaska Native, and those who
reported multiple races/ethnicities). There were 4 categories
of family income level expressed as a proportion of the federal
poverty level: <100%, 100% to 200%, 200% to 400%, and
≥400%.
Statistical Analysis
All analyses were conducted using STATA 14 (StataCorp). We
accounted for the complex sampling design of MEPS in all our
analyses using the ﬁnal person-weight and variance estima-
tions (person sampling and strata). We determined the
prevalence of each MRF and of the 3 MRF proﬁles and used
v2 statistics to test for their variations across different
sociodemographic characteristics. Because the distribution of
cost data is often right-skewed secondary to the high
proportion of people with no expenditure, we used a 2-part
model to estimate the marginal pharmaceutical expenditure
associated with each MRF (unfavorable versus favorable), the
3 MRF proﬁles, and the modiﬁed GCCI. The 2-part model
consists of (1) a binary choice model ﬁt for the probability of
observing a positive-versus-zero annual expenditure on med-
ications using the probit command and (2), contingent on
having >$0 annual pharmaceutical expenditure, a generalized
linear model (with c distribution and a log link) was ﬁtted for
the >$0 expenditure to estimate the effect of MRFs on
pharmaceutical expenditures.23,24 To determine the appropri-
ate distribution of the generalized linear model in the 2-part
model, we used the modiﬁed Park test.25 We used the margins
postestimation command to determine the marginal and
absolute pharmaceutical expenditures associated with the
predictor variables in the 2-part model. The use of the 2-part
model and the margins in STATA allowed us to estimate
robust standard errors, 95% conﬁdence intervals (CIs) and P
values associated with each estimate of marginal expenditure
(a level of signiﬁcance was 0.05). This also helped avoid the
difﬁculties associated with retransformation when ordinary
least squares with the log scale was used in analyzing highly
skewed expenditure data such as MEPS. In addition, because
the svy: twopm command can be used in STATA to incorporate
the complex design of MEPS in our analyses, our results can
be generalizable to the US population. However, the 2-part
model did not cause the data to become normal; the
skewness and kurtosis tests for normality among those with
positive cost value (ie, cost >0$) showed the distribution is
nonnormal (joint P<0.001).
Results
Sample Characteristics
From 2012 to 2013, there were 75 914 respondents in
MEPS, representing an average annual national estimate of
314.6 million individuals—similar to the average of the
projected US civilian population of 2012 and 2013. Among
this surveyed population, 4248 adults aged ≥40 years with a
BMI ≥18 had ASCVD (an annual equivalent of 21.9 million US
adults). The mean age was 67.7 years (SD 21.6), and 44.8%
were female.
The distribution of demographic characteristics for the
study population is shown in Table S3. The prevalence and the
variation of the prevalence of each MRF are shown in Table 1.
Hypertension was the most common MRF among ASCVD
adults, with a prevalence of 81.5%. Smoking and obesity were
signiﬁcantly more prevalent among adults aged 40 to
65 years, whereas the prevalence of dyslipidemia was higher
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among those aged 65 to 79 years; men were more likely to
have hyperlipidemia than women. Most of the study partic-
ipants (49.9%) reported an average MRF proﬁle, and with the
exception of sex, there was signiﬁcant variation in the
prevalence of MRF proﬁles across different sociodemographic
characteristics (Table S4).
Annual Pharmaceutical Expenditures Among
Those With ASCVD
Of the 4248 adults with ASCVD in 2012–2013, 95.4% used
prescription medications; 86.8% used ≥1 CVD medication. The
annual per capita pharmaceutical expenditures among adults
with ASCVD was $3432. On average, 34% of total pharmaceu-
tical expenditure was spent on CVD medications ($1139; 95%
CI, $1063–1215), and 14% ($482; 95% CI, $407–556) was
spent on antidiabetic medications. The residual 52% ($1786)
was for medications other than those for CVD and diabetes
(Figure 1). When projected using MEPS’s complex designs, the
2012–2013 annual total pharmaceutical spending among
those with ASCVD was an estimated $71.6 billion; $23.8 bil-
lion was spent on CVD medications, $10 billion was spent on
diabetes medications, and approximately $37.8 billion was
spent on other medications.
Effects of MRFs on Annul Pharmaceutical
Expenditures Among Those With ASCVD
The unadjusted and adjusted marginal pharmaceutical expen-
ditures associated with the presence versus absence of
individual MRFs is shown in Table 2. Inadequate physical
activity, dyslipidemia, hypertension, and diabetes mellitus
were statistically signiﬁcantly associated with total pharma-
ceutical expenditure after adjusting for sociodemographic
characteristics and burden of comorbid conditions. The
marginal pharmaceutical expenditure associated with dia-
betes mellitus was the highest of all MRFs at $2006 (95% CI,
$1470–$2542; P<0.001). When different categories of med-
ication expenditures were examined, dyslipidemia, hyperten-
sion, and diabetes mellitus were signiﬁcantly associated with
increased CVD medication expenditures; obesity and diabetes
mellitus were associated with increased expenditures for
diabetes medication; and inadequate physical activity and
hypertension were signiﬁcantly associated with an increase in
non-CVD, nondiabetic medication expenditures.
The average annual pharmaceutical expenditure among
patients with ASCVD who had an optimal MRF proﬁle was
$1400 (95% CI, $1073–1728) compared with $2672 (95% CI,
$2332–3013) among those with an average MRF proﬁle and
$4516 (95% CI, $4067–4965) among those with a poor MRF
$1,139 (34%)
$482 (14%)
$1,786 (52%)
CVD Agents
Anti-Diabetes Agents
Others Medications
$341 
$84 
$100 
$44 
$119 
$77 
$185 
$301 
$343 
$184 
Other Medications
Psychotherapeutic Medications
CNS Medications
RS Medications
GI Medications
Homorne Modifiers
Immunologic Drugs
Anti-Neoplastic Medications 
Anti-infective Medications
Rheumatologic Medications
Miscellaneous Medications
$403 
$382 
$287 
$23 $20 
$25 
CVD Medications
Other CVD medications
Anti-arrhythmias
Anti-anginas
Coagulation Modifiers
Antihypertensives
Anti-hyperlipidimeias
Figure 1. Annual per capita pharmaceutical expenditures for different medication classes among adults with ASCVD, MEPS 2012–2013. All
costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular disease; CNS, central nervous system; CVD, central nervous
system; GI, gastrointestinal; MEPS, Medical Expenditure Panel Survey; RS, respiratory system.
DOI: 10.1161/JAHA.116.004996 Journal of the American Heart Association 5
Risk Factors and Pharmaceutical Expenditures Salami et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
Ta
bl
e
2.
M
ar
gi
na
lP
ha
rm
ac
eu
tic
al
Ex
pe
nd
itu
re
s
As
so
ci
at
ed
W
ith
Ea
ch
M
RF
:
Re
su
lts
Fr
om
th
e
2-
Pa
rt
Ec
on
om
et
ric
M
od
el
,
M
EP
S
20
12
–2
01
3
M
RF
U
ni
va
ria
te
(U
na
dj
us
te
d)
M
od
el
1*
M
od
el
2†
M
ar
gi
na
lE
xp
en
di
tu
re
s
(9
5%
C
I)
P
Va
lu
e
M
ar
gi
na
lE
xp
en
di
tu
re
s
(9
5%
C
I)
P
Va
lu
e
M
ar
gi
na
lE
xp
en
di
tu
re
s
(9
5%
C
I)
P
Va
lu
e
Ov
er
al
lp
ha
rm
ac
eu
tic
al
ex
pe
nd
itu
re
s
In
ad
eq
ua
te
vs
op
tim
al
ph
ys
ic
al
ac
tiv
ity
86
4
(3
36
–1
39
1)
0.
00
1‡
89
3
(4
30
–1
35
5)
<
0.
00
1‡
52
0
(1
21
–9
18
)
0.
01
1‡
Ob
es
ity
vs
no
rm
al
BM
I
12
71
(7
26
–1
81
7)
<
0.
00
1‡
11
46
(6
75
–1
61
6)
<
0.
00
1‡
34
9
(
10
6
to
80
30
0.
13
2
Cu
rr
en
tly
sm
ok
in
g
vs
no
ns
m
ok
er
71
9
(2
9–
14
09
)
0.
00
7‡
41
1
(
26
7
to
10
90
)
0.
23
3
40
0
(
23
7
to
10
37
)
0.
21
7
Dy
sl
ip
id
em
ia
vs
no
dy
sl
ip
id
em
ia
10
31
(3
96
–1
66
6)
0.
00
2‡
11
43
(6
27
–1
65
9)
<
0.
00
1‡
63
1
(1
68
–1
09
4)
0.
00
8‡
Hy
pe
rte
ns
io
n
vs
no
hy
pe
rte
ns
io
n
16
79
(1
26
1–
20
96
)
<
0.
00
1‡
16
79
(1
30
2–
20
56
)
<
0.
00
1‡
10
79
(6
97
–1
46
0)
<
0.
00
1‡
Di
ab
et
es
m
el
lit
us
vs
no
di
ab
et
es
m
el
lit
us
25
57
(1
99
7–
31
17
)
<
0.
00
1‡
25
64
(2
02
0–
31
08
)
<
0.
00
1‡
20
06
(1
47
0–
25
42
)
<
0.
00
1‡
CV
D
m
ed
ic
at
io
n
ex
pe
nd
itu
re
s
In
ad
eq
ua
te
vs
op
tim
al
ph
ys
ic
al
ac
tiv
ity
11
8
(
32
to
26
8)
0.
12
3
14
2
(
8
to
29
1)
0.
06
3
73
(
76
to
22
2)
0.
33
3
Ob
es
ity
vs
no
rm
al
BM
I
22
3
(7
4–
37
30
0.
00
4‡
27
2
(1
23
–4
22
)
<
0.
00
1
14
1
(
24
to
30
5)
0.
09
3
Cu
rr
en
tly
sm
ok
in
g
vs
no
ns
m
ok
er
65
(
14
8
to
27
8)
0.
55
1
14
5
(
73
to
36
3)
0.
19
0
81
(
11
1
to
27
3)
0.
40
8
Dy
sl
ip
id
em
ia
vs
no
dy
sl
ip
id
em
ia
64
9
(5
02
–7
95
)
<
0.
00
1‡
63
1
(4
89
–7
74
)
<
0.
00
1‡
50
6
(3
50
–6
63
)
<
0.
00
1‡
Hy
pe
rte
ns
io
n
vs
no
hy
pe
rte
ns
io
n
57
4
(4
26
–7
23
)
<
0.
00
1‡
56
7
(4
20
–7
15
)
<
0.
00
1‡
39
4
(2
30
–5
58
)
<
0.
00
1‡
Di
ab
et
es
m
el
lit
us
vs
no
di
ab
et
es
m
el
lit
us
35
7
(2
02
–5
12
)
<
0.
00
1‡
40
6
(2
54
–5
57
)
<
0.
00
1‡
23
5
(7
7–
39
3)
0.
00
4‡
Di
ab
et
es
m
ed
ic
at
io
n
ex
pe
nd
itu
re
s
In
ad
eq
ua
te
vs
op
tim
al
ph
ys
ic
al
ac
tiv
ity
25
3
(1
20
–3
86
)
<
0.
00
1‡
25
5
(1
21
–3
88
)
<
0.
00
1‡
10
1
(
23
to
22
6)
0.
11
0
Ob
es
ity
vs
no
rm
al
BM
I
50
2
(3
15
–6
88
)
<
0.
00
1‡
47
6
(2
97
–6
56
)
<
0.
00
1‡
22
7
(9
4–
36
0)
0.
00
1‡
Cu
rr
en
tly
sm
ok
in
g
vs
no
ns
m
ok
er
53
(
17
1
to
27
65
)
0.
64
3
1
5
(
21
3
to
18
3)
0.
88
2
11
6
(
80
to
31
2)
0.
24
5
Dy
sl
ip
id
em
ia
vs
no
dy
sl
ip
id
em
ia
16
8
(1
0–
32
5)
0.
03
7‡
17
8
(2
3–
33
3)
0.
02
4‡
4
0
(
19
4
to
11
4)
0.
60
8
Hy
pe
rte
ns
io
n
vs
no
hy
pe
rte
ns
io
n
31
1
(1
53
–4
69
)
<
0.
00
1‡
32
8
(1
98
–4
59
)
<
0.
00
1‡
77
(
75
to
22
8)
0.
32
0
Di
ab
et
es
m
el
lit
us
vs
no
di
ab
et
es
m
el
lit
us
13
99
(1
19
3–
16
06
)
<
0.
00
1‡
15
40
(1
14
5–
19
34
)
<
0.
00
1‡
12
96
(1
10
8–
14
84
)
<
0.
00
1‡
Ot
he
r
m
ed
ic
at
io
n
ex
pe
nd
itu
re
s
In
ad
eq
ua
te
vs
op
tim
al
ph
ys
ic
al
ac
tiv
ity
44
3
(
25
to
91
1)
0.
06
3
48
0
(1
35
–8
25
)
0.
00
7‡
31
9
(1
6–
62
2)
0.
03
9‡
Ob
es
ity
vs
no
rm
al
BM
I
52
0
(6
1–
97
9)
0.
02
7‡
34
0
(
25
to
70
4)
0.
06
8
77
(
31
5
to
46
9)
0.
69
8
Cu
rr
en
tly
sm
ok
in
g
vs
no
ns
m
ok
er
77
6
(1
87
–1
36
6)
0.
01
‡
32
4
(
18
1
to
82
8)
0.
20
7
24
0
(
24
8
to
72
8)
0.
33
3
Dy
sl
ip
id
em
ia
vs
no
dy
sl
ip
id
em
ia
22
(
61
4
to
65
8)
0.
94
6
16
0
(
29
6
to
61
6)
0.
49
0
1
44
(
56
8
to
28
0)
0.
50
4
Hy
pe
rte
ns
io
n
vs
no
hy
pe
rte
ns
io
n
62
6
(3
14
–9
38
)
<
0.
00
1‡
60
4
(3
29
–8
78
)
<
0.
00
1‡
49
2
(2
19
–7
65
)
<
0.
00
1‡
Di
ab
et
es
m
el
lit
us
vs
no
di
ab
et
es
m
el
lit
us
69
7
(2
75
–1
12
0)
0.
00
1‡
61
1
(2
42
–9
79
)
0.
00
1‡
38
6
(1
3–
75
9)
0.
04
2‡
Al
lc
os
t
ar
e
in
20
13
U
S
do
lla
rs
.
BM
I
in
di
ca
te
s
bo
dy
m
as
s
in
de
x;
C
I,
co
nﬁ
de
nc
e
in
te
rv
al
;
C
VD
,
ca
rd
io
va
sc
ul
ar
di
se
as
e;
M
EP
S,
M
ed
ic
al
Ex
pe
nd
itu
re
Pa
ne
lS
ur
ve
y;
M
RF
,m
od
iﬁ
ab
le
ris
k
fa
ct
or
.
*M
od
el
1:
Ea
ch
M
RF
w
as
us
ed
as
a
pr
ed
ic
to
r
an
d
ad
ju
st
ed
fo
r
ag
e,
se
x,
ra
ce
/e
th
ni
ci
ty
,
an
d
in
co
m
e
le
ve
l(
al
lv
ar
ia
bl
e
en
te
re
d
as
ca
te
go
ric
al
va
ria
bl
es
).
†
M
od
el
2:
Al
lM
RF
s
w
er
e
en
te
re
d
si
m
ul
ta
ne
ou
sl
y
an
d
ad
ju
st
ed
fo
r
ag
e,
se
x,
ra
ce
/e
th
ni
ci
ty
,
in
co
m
e
le
ve
l,
an
d
C
ha
rls
on
C
om
or
bi
di
ty
In
de
x
(a
ll
va
ria
bl
es
en
te
re
d
as
ca
te
go
ric
al
va
ria
bl
es
).
‡
St
at
is
tic
al
ly
si
gn
iﬁ
ca
nt
.
DOI: 10.1161/JAHA.116.004996 Journal of the American Heart Association 6
Risk Factors and Pharmaceutical Expenditures Salami et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
proﬁle. The unadjusted and adjusted marginal pharmaceutical
expenditures associated with MRF proﬁles are shown in
Table 3. After accounting for demographics, income status,
and comorbid conditions, the annual pharmaceutical
expenditure was $1184 (95% CI, $805–1564) higher among
those with average MRF proﬁles and $2823 (95% CI, $2338–
3307) higher among ASCVD patients with poor MRF proﬁles
compared with those with optimal MRF proﬁles (P<0.001).
Table 3. Per Capita Marginal Pharmaceutical Expenditures Associated With Grouped MRFs and Charlson Comorbidity Index
Among Adults With ASCVD, MEPS 2012–2013
MRF Proﬁle Unadjusted Adjusted*
Overall pharmaceutical expenditures† (95% CI)
Optimal MRF Reference P value Reference P-value
Average MRF 1272 (844–1700) <0.001‡ 1184 (804–1564) <0.001‡
Poor MRF 3115 (2645–3586) <0.001‡ 2823 (2338–3308) <0.001‡
CVD-medication expenditures (95% CI)
Optimal MRF Reference P value Reference P value
Average MRF 396 (200–591) <0.001‡ 406 (231–582) <0.001‡
Poor MRF 791 (589–993) <0.001‡ 848 (653–1043) <0.001‡
Diabetes medication expenditures (95% CI)
Optimal MRF Reference P value Reference P value
Average MRF 136 (84–188) <0.001‡ 131 (77–185) <0.001‡
Poor MRF 969 (797–1141) <0.001‡ 943 (760–1126) <0.001‡
Other medication expenditures (95% CI)
Optimal MRF Reference P value Reference P value
Average MRF 622 (199–1045) 0.004‡ 526 (134–918) 0.009‡
Poor MRF 1167 (773–1560) <0.001‡ 807 (434–1180) <0.001‡
Modiﬁed Grouped CCI Unadjusted Adjusted§
Overall pharmaceutical expenditures† (95% CI)
0 Reference P value Reference P value
1 2603 (1723–3483) <0.001‡ 2272 (1519–3025) <0.001‡
2 2518 (1665–3371) <0.001‡ 2068 (1349–2787) <0.001‡
CVD-medication expenditures (95% CI)
0 Reference P value Reference P value
1 53 (130 to 236) 0.567 21 (153 to 195) 0.811
2 132 (70 to 334) 0.2‡ 30 (169 to 229) 0.77
Diabetes medication expenditures (95% CI)
0 Reference P value Reference P value
1 159 (21–297) <0.024‡ 29 (101 to 160) <0.001‡
2 375 (94–656) 0.009‡ 206 (1–411) 0.048
Other medication expenditures (95% CI)
0 Reference P value Reference P value
1 2312 (1514–3111) <0.001‡ 2015 (1412–2617) <0.001‡
2 1903 (1274–2532) <0.001‡ 1773 (1189–2357) <0.001‡
All costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular disease; CCI, Charlson Comorbidity Index; CI, conﬁdence interval; CVD, cardiovascular disease; MRF,
modiﬁable risk factors; MEPS, Medical Expenditure Panel Survey.
*Adjusted for age, sex, race/ethnicity, income level, CCI.
†All Costs are in 2013 USD.
‡Statistically signiﬁcant.
§Adjusted for age, sex, race/ethnicity, income level, and grouped MRFs category.
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Similar trends were noted when mean expenditures for
speciﬁc medication classes (CVD, diabetes, and other) were
considered.
Figure 2 describes the association among both MRF
proﬁles and increasing burden of comorbid conditions with
annual pharmaceutical expenditures (overall and medication-
speciﬁc). The lowest annual drug costs were observed among
those with optimal MRF proﬁles and no major comorbid
conditions ($1386). In contrast, ASCVD patients with poor
MRF proﬁles and a GCCI of 2 had the highest annual
pharmaceutical expenditures ($6948). Across worsening
comorbidity, individuals with poor MRF proﬁles incurred the
highest pharmaceutical expenditures (Figure 2). In a subanal-
ysis of speciﬁc CVD medications, annual costs of antihyper-
lipidemics, antihypertensives, and coagulation modiﬁers
signiﬁcantly increased with worsening MRF proﬁle across all
categories of comorbidity burden (Figure 3).
Discussion
In a nationally representative population, our study demon-
strated that in 2012–2013, adults with established ASCVD
spent $284 billion on health care per annum. Of this,
$71.6 billion was spent on medications. The contributions
of medications for CVD and diabetes mellitus to the overall
pharmaceutical expenditures were $23.8 billion (34%) and
$10 billion (14%), respectively. More than half (52%) of the
overall pharmaceutical expenditure was spent on non-CVD,
nondiabetes medications. The details of the 2012–2013 per
capita pharmaceutical expenditures examined in the context
of the mean healthcare expenditures in our study population
are shown in Figure S2. The overall pharmaceutical expendi-
ture was signiﬁcantly associated with individual MRFs;
inadequate physical activity, dyslipidemia, hypertension, and
diabetes mellitus as well as worsening MRF proﬁle were all
associated with higher pharmaceutical expenditure. Similar
patterns were observed when expenditures for speciﬁc
medication classes (CVD, diabetes, and others) were exam-
ined. These associations persisted even after accounting for
underlying comorbid conditions.
Many studies have found that current MRFs are important
drivers of future morbidity and mortality among individuals
with established CVD in a dose-response fashion.26–28
Although studies within and outside the United States have
attempted to estimate the incremental healthcare expendi-
tures associated with individual cardiovascular MRFs among
those without established CVD,29,30 no study has detailed the
potential economic impact of CVD MRFs on pharmaceutical
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-
Figure 2. Mean pharmaceutical expenditures associated with grouped MRFs across different levels of grouped CCI among those with ASCVD,
MEPS 2012–2013. Mean expenditures were estimated using the person weight and variance estimation stratum and person sampling unit of
MEPS 2012–2013. All costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular disease; CCI, Charlson Comorbidity Index;
CVD, cardiovascular disease; MEPS, Medical Expenditure Panel Survey; MRF, modiﬁable risk factor.
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costs, which remains one of the largest contributors to overall
healthcare expenditures. Sullivan et al showed that among
persons with cardiometabolic risk factor clusters (BMI ≥25
and any 2 of hypertension, hyperlipidemia, and diabetes
mellitus), 34% of total healthcare expenditure was for
prescription medications in 2006,10 and depending on the
source of payment, the proportion could be as high as 49%.8
In Australia, Ademi et al showed that obesity, hypertension,
and diabetes mellitus are predictors of higher pharmaceutical
expenditures among persons with or at risk of CVD.29
The ﬁndings of Ademi et al are similar to ours. Our study of
the US adults with ASCVD in 2012–2013 showed that
individual cardiovascular MRFs such as inadequate physical
activity, dyslipidemia, hypertension, and diabetes mellitus
were signiﬁcantly associated with higher pharmaceutical
expenditures of $519, $631, $1078, and $2006, respectively,
compared with adults without the respective risk factors, after
accounting for sociodemographic factors and comorbidity. In
addition, we found signiﬁcantly higher pharmaceutical expen-
ditures (all medications, CVD-speciﬁc medications, and non-
CVD pharmaceutical expenditures) associated with poor
cardiovascular MRF proﬁles among persons with established
ASCVD in a nationally representative cohort, after accounting
for underlying comorbid conditions. The adjusted average
annual pharmaceutical expenditure was highest among those
with a poor MRF proﬁle ($4516) and lowest for those with an
optimal MRF proﬁle ($1400).
Another signiﬁcant ﬁnding of our study is that although the
study population consisted of those with established ASCVD,
non-CVD medications contributed the most toward total
pharmaceutical cost. This is comparable to the ﬁndings of the
Cooper Center Longitudinal Study by Willis et al, in which they
reported that average annual non-CVD healthcare cost was
higher than CVD-related healthcare cost and that overall cost
increased with worsening MRF proﬁle.30 These ﬁndings are
not unexpected considering the complex interplay among
CVD, MRFs, and associated comorbidities31 in increasing
healthcare resource utilization and cost.
Some studies have demonstrated an association between
comorbidity and healthcare costs.32–34 In our study, comor-
bidity was found to be associated with higher pharmaceutical
expenditure among people with established ASCVD. Beyond
that, our study also demonstrated that the burden of
cardiovascular MRF may have a higher impact on pharma-
ceutical expenditure than the burden of other comorbid
conditions among those with ASCVD. The marginal
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Figure 3. Mean CVD medication expenditures and their association with MRF proﬁles across different levels of grouped CCI among those with
ASCVD, MEPS 2012–2013. Mean expenditures were estimated using the person weight, variance estimation stratum, and person sampling unit
of MEPS 2013. All costs are in 2013 US dollars. ASCVD indicates atherosclerotic cardiovascular diseases; CCI, Charlson Comorbidity Index;
CVD, cardiovascular disease; MEPS, Medical Expenditure Panel Survey; MRF, modiﬁable risk factor.
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pharmaceutical expenditures associated with worsening MRF
proﬁles were larger than those associated with a higher
burden of comorbid conditions (see Table 3). This under-
scores the importance of addressing MRF prevention in the
general population, especially because the prevention of
MRFs reduces the risk of ASCVD. This approach can
potentially lead to pharmaceutical cost saving and, ultimately,
reduced healthcare spending.
As projected, 40.5% of the US population will have a type
of CVD by 2030 and will spend $818 billion in annual direct
medical cost—a signiﬁcant leap from the $217 billion spent
in 2010.1 It is imperative that all possible means targeted at
stalling or halting this projected economic impact of CVD be
explored today. An integrated approach to the management of
ASCVD, its associated MRFs, and other comorbidities could
be explored to reduce spending. The concept of “bundle
payment” in the “one cycle of care”35 may be adapted to
prescription medications and explored among ASCVD
patients, perhaps taking the approach of “one price for a
year’s supply” to prescriptions used in managing chronic
conditions. The use of the payment-for-outcome approach in
prescription medication can also encourage pharmacists and
clinicians to improve on quality, rather than quantity, of
services. Careful monitoring of healthcare costs and
outcomes must be implemented for early identiﬁcation of
negative trends and prompt institution of mitigation
measures.
This study has several strengths. First, MEPS’s careful
design and execution involved multilevel veriﬁcation of
information collected from participants.36 Second, the over-
sampling of minority race/ethnicity such as Hispanic and
black make results generalizable to all races in the United
States. Third, the large sample size allowed us to adequately
characterize persons with ASCVD by MRFs and yet have
enough participants to estimate marginal expenditures asso-
ciated with MRFs. The results of our study, however, must be
interpreted in the context of the following limitations. First, we
were limited to the 3-digit ICD-9-CM code used to map
medical conditions, which means our observed prevalence of
ASCVD may be underestimated. Second, because cardiovas-
cular MRFs were self-reported, the true national prevalence is
likely underestimated.37 Third, the use of the Multum Lexicon
drug classiﬁcation system, although apt for drug classiﬁca-
tion, may overestimate expenditures for CVD medications
because some CVD medications may have non-CVD uses.
Fourth, MEPS does not account for over-the-counter prescrip-
tion expenditures, and this may also underestimate the
average pharmaceutical expenditures. Fifth, MEPS was con-
ducted among noninstitutionalized US civilians, and thus our
results are nonrepresentative of the entire US population.
Finally, although we comprehensively controlled for variables
chosen based on existing knowledge of factors associated
with higher pharmaceutical expenditures and scientiﬁc selec-
tion of statistical models using Akaike’s criteria, there may be
unobserved characteristics that affect the outcomes studied,
causing residual confounding; factors such as health insur-
ance, clinicians, pharmacists, healthcare organization, drug
companies, and even patient behaviors are important deter-
minants of pharmaceutical expenditures that could not be
assessed in this study.
Conclusion
Some individual MRFs and worsening MRF proﬁles among
persons with established ASCVD are associated with a higher
annual pharmaceutical expenditure. Future studies are
needed to demonstrate whether patient-centered pragmatic
approaches to manage and prevent MRFs will curtail the rising
pharmaceutical expenditures (on all medications and CVD-
speciﬁc medications) among those with ASCVD.
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Table S1. ICD-9 CM codes of diseases classified as ASCVD, and Multum Lexicon Drug Codes for CVD,  Diabetic, and other Major Medication Classes 
PANEL A PANEL B 
ICD-9-CM 
Code 
Disease description 
Multum 
Lexicon Drug 
Code (s) 
Drug description 
410 Acute myocardial infarction CVD Medications 
413 Angina pectoris 
41-44, 47-49, 
53, 55, 56 Anti-hypertensive agents 
414 Other forms of chronic ischemic heart disease: 46 Anti-arrhythmic agents 
414 Coronary atherosclerosis 45 Anti-angina agents 
414.1 Aneurysm and dissection of heart 19  Antihyperlipidemic agents 
414.2 Chronic total occlusion of coronary artery 81 Coagulation modifiers 
414.3 Coronary atherosclerosis due to lipid rich plaque 40† Other CVD Medications 
414.4 Coronary atherosclerosis due to calcified coronary lesion 
Non-CVD  
Medications Non-CVD  Medications 
414.8 Other specified forms of chronic ischemic heart disease 99 Antidiabetic drugs 
414.9 Chronic ischemic heart disease, unspecified 242 Psychotherapeutic drugs 
433 Pre-cerebral occlusion 57 Central Nervous System drugs 
434 Cerebral artery occlusion 122 Respiratory System drugs 
435 Transient cerebral ischemia 87 Gastrointestinal System drugs 
436 Cerebrovascular accident 254 Immunologic drugs 
437 Other cerebrovascular disease 20 Anti-Neoplastic drugs 
440 Atherosclerosis 1 Anti-infective drugs 
443 Other peripheral vascular diseases: 
192, 194, 
270 Rheumatologic drugs 
447 Other arterial diseases 
98, 100, 103, 
217, 295 Hormones and endocrine drugs (excluding anti-diabetic drugs) 
447 Other arterial diseases 
Abbreviations: ASCVD, Atherosclerotic Cardiovascular Diseases; CVD, Cardiovascular Disease; ICD-CM, International Classification of Diseases, 9th Revision, Clinical Modification; ACE, Angiotensin 
Converting Enzymes 
†Excluding the antihypertensive, anti-arrhythmic, and anti-angina drugs. 
Table S2. Charlson Comorbidity Index (CCI) Scoring System 
Score Condition 
1 Myocardial Infarction ** 
Congestive heart failure 
Peripheral vascular disease ** 
Cerebrovascular disease ** 
Chorionic pulmonary disease 
Dementia 
Connective tissue disease 
Peptic ulcer disease 
Mild liver disease (without portal hypertension) 
Diabetes (without end-organ damage) ** 
2 Diabetes (with end-organ damage) ** 
Hemiplegia 
Renal disease (moderate or severe) 
Tumor (without metastasis) 
Leukemia (acute or chronic) 
Lymphoma 
3 Liver illness (moderate or severe) 
6 Tumor, with metastasis 
AIDS 
** Diseases excluded from our modified CCI 
Table S3. Socio Demographic Characteristics of Adults Aged 40 years 
and Older living with ASCVD, MEPS 2012-2013 
No. of Survey 
Participants 
US 
Population 
Equivalent 
(Million) 
Proportion 
(%) 
Overall 
4,248 
21.9 100.00% 
Age group (yrs) 
40-64 
1,647 
8.5 38.8% 
65-79 
1,203 
6.2 28.3% 
>=80 
1,398 
7.2 32.9% 
Sex 
Men 
2,345 
12.1 55.2% 
Women 
1,903 
9.8 44.8% 
Race/ethnicity 
Non-Hispanic White 
3,191 
16.4 75.1% 
Non-Hispanic Black 
485 
2.5 11.4% 
Asian 
107 
0.5 2.5% 
Hispanic 
375 
1.9 8.8% 
Other 
90 
0.5 2.1% 
Family income level* 
<100% 
646 
3.3 15.2% 
100-200%
1,027 
5.3 24.2% 
200-400%
1,185 
6.1 27.9% 
>400%
1,390 
7.2 32.7% 
GCCI 
0 
2,866 
14.8 67.5% 
1 
867 
4.5 20.4% 
2 
515 
2.7 12.1% 
Abbreviations: Atherosclerotic Cardiovascular Diseases; MEPS, Medical 
Expenditure Panel Survey; GCCI, Grouped Charlson Comorbidity Index 
* Family Income  expressed as a proportion of the Federal Poverty Level
Table S4. Prevalence of Modifiable Risk Factor Profile Across Socio-demographic characteristics of Adults 
Aged ≥40 years living with ASCVD , MEPS 2012-2013 
Prevalence % (95% CI) 
No. of 
Survey 
Participants 
Optimal MRF 
[0-1 MRF] 
Average MRF  
[2-3 MRFs] 
Poor MRF 
[≥4 MRFs] 
P value† 
Overall 4,248 10.4 (9.0-11.8) 49.9 (47.7-52.2) 39.7 (37.5-42.0) 
Age group (Yrs) 
40-64 1,647 11.7 (9.7-14.0) 45.0 (42.0-48.0) 43.3 (40.2-46.5) 
65-79 1,203 9.1 (6.7-12.1) 48.3 (44.5-52.1) 42.7 (38.9-46.5) 0.0002 
>=80 1,398 9.9 (7.5-13.0) 57.2 (52.8-61.5) 32.9 (28.7-37.3) 
Sex 
Men 2,345 9.4 (7.7-11.5) 50.8 (47.8-53.7) 39.8 (36.8-42.9) 0.8542 
Women 1,903 11.5 (9.4-13.9) 48.9 (45.8-52.0) 39.6 (36.6-42.7) 
Race/ethnicity 
Non-Hispanic White 3,191 11.0 (9.4-12.9) 51.3 (48.5-54.0) 37.7 (35.1-40.3) 
Non-Hispanic Black 485 6.6 (4.9-8.7) 45.6 (41.4-49.8) 47.9 (43.5-52.2) 
Asian 107 13.0 (8.1-20.3) 57.8 (47.5-67.5) 29.2 (21.0-38.9) <0.001 
Hispanic 375 9.4 (7.2-12.2) 45.7 (40.9-50.5) 44.9 (40.2-49.7) 
Other 90 7.4 (2.5-20.0) 33.4 (21.6-47.9) 59.2 (45.6-71.5) 
Family income level* 
<100% 646 8.2 (5.9-11.3) 44.1 (39.2-49.1) 47.7 (42.9-52.6) 
100-200% 1,027 8.0 (6.0-10.6) 50.5 (46.6-54.5) 41.4 (37.8-45.2) <0.001 
200-400% 1,185 9.2 (6.9-12.1) 50.4 (45.7-55.1) 40.4 (36.1-44.9) 
>400% 1,390 14.1 (11.5-17.2) 51.8 (47.8-55.8) 34.1 (30.1-38.3) 
GCCI 
0 2,866 12.1 (10.5-13.9) 52.4 (49.9-54.8) 35.6 (33.0-38.2) 
1 867 9.0 (6.0-13.4) 42.7 (38.1-47.4) 48.3 (44.152.5) <0.001 
2 515 3.1 (1.6-5.7) 48.6 (42.4-54.9) 48.3 (41.8-54.8) 
Abbreviations: ASCVD, Atherosclerotic cardiovascular Disease; MEPS, Medical Expenditure Panel Survey; CI, 
Confidence Interval; GCCI, Grouped Charlson Comorbidity Index 
* Family Income  expressed as a proportion of the Federal Poverty Level
† χ2 Statistic used to test difference in proportions between respondents 
Figure S1. Flow Chart Showing the Study Population Selection, MEPS 2012-2013 
Figure S2. Mean Healthcare Expenditure Across MRF Profile and Charlson Comorbidity Index 
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